Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Gossamer Bio and keeping the price target at $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors related to Gossamer Bio’s promising developments in their pulmonary arterial hypertension (PAH) treatment program. The company’s lead candidate, seralutinib, is highlighted for its potential to modify disease progression through a reverse-remodeling mechanism, which is a significant advancement over existing vasodilator therapies. The ongoing Phase 3 PROSERA trial is expected to deliver top-line data by February 2026, with a primary endpoint focused on the six-minute walk distance (6MWD), which is anticipated to de-risk the program further.
Additionally, Gossamer Bio’s management has emphasized the trial’s design, which includes enrichment criteria that may increase the likelihood of demonstrating a clinically meaningful benefit in a more impaired patient population. The company also draws attention to the long-term durability data from the Phase 2 TORREY open-label extension, which supports the efficacy of seralutinib. The upcoming Phase 3 SERANATA trial, targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), is set to begin in late 2025 and could further solidify seralutinib’s position in the market. These strategic developments and trial designs have reinforced Trucchio’s confidence in the stock’s potential, leading to the reiterated Buy rating.
In another report released on September 11, Cantor Fitzgerald also maintained a Buy rating on the stock with a $0.00 price target.